|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 237.70 EUR | +0.85% |
|
-4.42% | -0.38% |
| 07-14 | Where would AI lead Pharma in the long run? |  |
| 07-13 | Antengene Receives $60 Million Milestone in UCB Licensing Deal | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 51.32B | |||||
| 67.6B | |||||
| 42.97B | |||||
| 40.81B | - | ||||
| 29.12B | |||||
| 27.09B | - |
- Stock Market
- Stocks
- UCB Stock
- Charts UCB
- Sector Chart
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
